Compares morning and evening dosing of a JAK inhibitor in rheumatoid arthritis
Compares morning and evening doses of a JAK inhibitor in adults with rheumatoid arthritis.
Plain-language title generated from the registry record
Registry title: Comparison of Oral Administration of a JAK Inhibitor in Rheumatoid Arthritis
Key facts
- Where
- Monaco, MonacoSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with rheumatoid arthritis who are starting a JAK inhibitor. It compares taking the tablet in the morning with taking it in the evening.
- Age
- Over 18 years
- Sex
- All sexes can join.
- Disease stage
- Rheumatoid arthritis by the 2010 ACR/EULAR criteria, meeting the criteria for starting a JAK inhibitor.
- Earlier treatment
- No earlier treatment with a JAK inhibitor. Stable doses of corticosteroids and of maintenance therapy in the 4 weeks before enrolment.
Main reasons for not taking part
- Earlier treatment with a JAK inhibitor
- Not stable dose of corticosteroids or maintenance therapy in the 4 weeks before enrolment
- Pregnant or breastfeeding
- Cannot be followed in the study for 6 months
- Refuses effective contraception during the study
Read by machine on 9 November 2026.
Where in Monaco
- Centre Hospitalier Princesse GraceMonaco, MonacoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Princesse Grace
- Trial code
- NCT07674134
- Record updated
- 29 June 2026
- Original description
The aim of this study is to offer patients two treatment options: morning or evening administration of a JAK inhibitor prescribed within the framework of its marketing authorization, according to the EULAR response.Read full original descriptionShow less
Comparison of Morning Versus Evening Oral Administration of a JAK Inhibitor in Rheumatoid Arthritis
The aim of this study is to offer patients two treatment options: morning or evening administration of a JAK inhibitor prescribed within the framework of its marketing authorization, according to the EULAR response.
The objective is to determine whether evening administration in our patients with rheumatoid arthritis provides greater efficacy than morning administration in our patients taking JAK inhibitors once daily.
Inclusion: Patient aged over 18 years; Patient with Rheumatoid Arthritis according to the 2010 ACR/EULAR criteria; Patient meeting the criteria for initiation of a JAK inhibitor according to the marketing authorization and international recommendations; Patient capable of providing informed, written, dated, and signed consent before the start of any trial-related procedure.
Exclusion: Not stable dose of corticosteroids in the 4 weeks preceding enrollment; Not stable dose of maintenance therapy (methotrexate, leflunomide, hydroxychloroquine, cyclosporine, gold salts) in the 4 weeks preceding enrollment; Prior treatment with a JAK inhibitor; No contraindication to a bDMARD; Patient unable to be followed-up in the study during 6 months; Minors or adults under guardianship or curatorship, or deprived of their liberty; Pregnant or breastfeeding patient; Patient refusing to use an effective method of contraception for the duration of the study; Person not affiliated with a social security scheme.